Your browser doesn't support javascript.
loading
Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials.
Diaz-Manera, Jordi; Fernandez-Torron, Roberto; LLauger, Jaume; James, Meredith K; Mayhew, Anna; Smith, Fiona E; Moore, Ursula R; Blamire, Andrew M; Carlier, Pierre G; Rufibach, Laura; Mittal, Plavi; Eagle, Michelle; Jacobs, Marni; Hodgson, Tim; Wallace, Dorothy; Ward, Louise; Smith, Mark; Stramare, Roberto; Rampado, Alessandro; Sato, Noriko; Tamaru, Takeshi; Harwick, Bruce; Rico Gala, Susana; Turk, Suna; Coppenrath, Eva M; Foster, Glenn; Bendahan, David; Le Fur, Yann; Fricke, Stanley T; Otero, Hansel; Foster, Sheryl L; Peduto, Anthony; Sawyer, Anne Marie; Hilsden, Heather; Lochmuller, Hanns; Grieben, Ulrike; Spuler, Simone; Tesi Rocha, Carolina; Day, John W; Jones, Kristi J; Bharucha-Goebel, Diana X; Salort-Campana, Emmanuelle; Harms, Matthew; Pestronk, Alan; Krause, Sabine; Schreiber-Katz, Olivia; Walter, Maggie C; Paradas, Carmen; Hogrel, Jean-Yves; Stojkovic, Tanya.
Afiliação
  • Diaz-Manera J; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain.
  • Fernandez-Torron R; Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • LLauger J; Neuromuscular Area, Biodonostia Health Research Institute, Neurology Service, Donostia University Hospital, Donostia-San Sebastian, Spain.
  • James MK; The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Newcastle upon Tyne, UK.
  • Mayhew A; Radiology Department, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Smith FE; The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Newcastle upon Tyne, UK.
  • Moore UR; The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Newcastle upon Tyne, UK.
  • Blamire AM; Magnetic Resonance Centre, Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Carlier PG; The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Newcastle upon Tyne, UK.
  • Rufibach L; Magnetic Resonance Centre, Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Mittal P; AIM & CEA NMR Laboratory, Institute of Myology, Pitié-Salpêtrière University Hospital, Paris, France.
  • Eagle M; The Jain Foundation, Seattle, Washington, USA.
  • Jacobs M; The Jain Foundation, Seattle, Washington, USA.
  • Hodgson T; The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Newcastle upon Tyne, UK.
  • Wallace D; Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, District of Columbia, USA.
  • Ward L; Department of Pediatrics, Epidemiology and Biostatistics, George Washington University, Washington, District of Columbia, USA.
  • Smith M; Magnetic Resonance Centre, Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Stramare R; Magnetic Resonance Centre, Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Rampado A; Magnetic Resonance Centre, Institute for Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Sato N; Department of Radiology, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Tamaru T; Radiology Unit, Department of Medicine, University of Padova, Padova, Italy.
  • Harwick B; Radiology Unit, Department of Medicine, University of Padova, Padova, Italy.
  • Rico Gala S; Department of Radiology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Turk S; Department of Radiology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Coppenrath EM; Department of Radiology, CMC Mercy Charlotte, Carolinas Healthcare System Neurosciences Institute, Charlotte, North Carolina, USA.
  • Foster G; Department of Radiology, Hospital U. Virgen de Valme, Sevilla, Spain.
  • Bendahan D; AIM & CEA NMR Laboratory, Institute of Myology, Pitié-Salpêtrière University Hospital, Paris, France.
  • Le Fur Y; Department of Clinical Radiology, Ludwig-Maximilians-University, Munich, Germany.
  • Fricke ST; Center for Clinical Imaging Research CCIR, Washington University, St. Louis, Missouri, USA.
  • Otero H; Centre de Résonance, Magnétique Biologique et Médicale, Marseille, France.
  • Foster SL; Aix-Marseille Université, Marseille, France.
  • Peduto A; Aix-Marseille Université, Marseille, France.
  • Sawyer AM; Department of Diagnostic Imaging and Radiology, Children's National Health System, Washington, District of Columbia, USA.
  • Hilsden H; Department of Diagnostic Imaging and Radiology, Children's National Health System, Washington, District of Columbia, USA.
  • Lochmuller H; Department of Radiology, Westmead Hospital, Westmead, New South Wales, Australia.
  • Grieben U; Faculty of Health Sciences, University of Sydney, Sydney, Australia.
  • Spuler S; Department of Radiology, Westmead Hospital, Westmead, New South Wales, Australia.
  • Tesi Rocha C; Faculty of Health Sciences, University of Sydney, Sydney, Australia.
  • Day JW; Lucas Center for Imaging, Stanford University School of Medicine, Stanford, California, USA.
  • Jones KJ; The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Newcastle upon Tyne, UK.
  • Bharucha-Goebel DX; The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Newcastle upon Tyne, UK.
  • Salort-Campana E; Charite Muscle Research Unit, Experimental and Clinical Research Center, A Joint Co-operation of the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Harms M; Charite Muscle Research Unit, Experimental and Clinical Research Center, A Joint Co-operation of the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Pestronk A; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Krause S; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Schreiber-Katz O; Institute for Neuroscience and Muscle Research, Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia.
  • Walter MC; Department of Neurology, Children's National Health System, Washington, District of Columbia, USA.
  • Paradas C; National Institutes of Health (NINDS), Bethesda, Maryland, USA.
  • Hogrel JY; Neuromuscular and ALS Center, La Timone Hospital, Aix-Marseille Université, Marseille, France.
  • Stojkovic T; Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
J Neurol Neurosurg Psychiatry ; 89(10): 1071-1081, 2018 10.
Article em En | MEDLINE | ID: mdl-29735511
ABSTRACT
BACKGROUND AND

OBJECTIVE:

Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathies had not been performed and previous imaging findings were not correlated with functional tests.

METHODS:

We present cross-sectional T1-weighted muscle MRI data from 182 patients with genetically confirmed dysferlinopathies. We have analysed the pattern of muscles involved in the disease using hierarchical analysis and presented it as heatmaps. Results of the MRI scans have been correlated with relevant functional tests for each region of the body analysed.

RESULTS:

In 181 of the 182 patients scanned, we observed muscle pathology on T1-weighted images, with the gastrocnemius medialis and the soleus being the most commonly affected muscles. A similar pattern of involvement was identified in most patients regardless of their clinical presentation. Increased muscle pathology on MRI correlated positively with disease duration and functional impairment.

CONCLUSIONS:

The information generated by this study is of high diagnostic value and important for clinical trial development. We have been able to describe a pattern that can be considered as characteristic of dysferlinopathy. We have defined the natural history of the disease from a radiological point of view. These results enabled the identification of the most relevant regions of interest for quantitative MRI in longitudinal studies, such as clinical trials. CLINICAL TRIAL REGISTRATION NCT01676077.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Músculo Esquelético / Distrofia Muscular do Cíngulo dos Membros Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Músculo Esquelético / Distrofia Muscular do Cíngulo dos Membros Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article